EA201692180A1 - Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации - Google Patents
Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизацииInfo
- Publication number
- EA201692180A1 EA201692180A1 EA201692180A EA201692180A EA201692180A1 EA 201692180 A1 EA201692180 A1 EA 201692180A1 EA 201692180 A EA201692180 A EA 201692180A EA 201692180 A EA201692180 A EA 201692180A EA 201692180 A1 EA201692180 A1 EA 201692180A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disability
- pprs
- patient
- multiple sclerosis
- remitting multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/112—Gait analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0076—Medicament distribution means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
В настоящем изобретении предложен способ лечения или уменьшения ухудшения ходьбы у человека с диагнозом рецидивирующе-ремиттирующий рассеянный склероз (РРРС) и наличием высокой исходной оценки инвалидизации по Расширенной шкале оценки степени инвалидизации Куртцке (EDSS), включающий периодическое введение только пациенту с диагнозом РРРС и наличием высокой исходной оценки инвалидизации количества лахинимода, эффективного для лечения пациента или уменьшения ухудшения ходьбы. В настоящем изобретении также предложены фармацевтические композиции и упаковки, включающие эффективное количество лахинимода для лечения пациента-человека с диагнозом РРРС и наличием высокой исходной оценки инвалидизации по EDSS.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461985886P | 2014-04-29 | 2014-04-29 | |
US201462046561P | 2014-09-05 | 2014-09-05 | |
US201562119506P | 2015-02-23 | 2015-02-23 | |
US201562139978P | 2015-03-30 | 2015-03-30 | |
PCT/US2015/027961 WO2015168103A1 (en) | 2014-04-29 | 2015-04-28 | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692180A1 true EA201692180A1 (ru) | 2017-08-31 |
Family
ID=54333761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692180A EA201692180A1 (ru) | 2014-04-29 | 2015-04-28 | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
Country Status (16)
Country | Link |
---|---|
US (3) | US20150306088A1 (ru) |
EP (1) | EP3137092A4 (ru) |
JP (1) | JP2017514824A (ru) |
KR (1) | KR20170005434A (ru) |
CN (1) | CN106573014A (ru) |
AU (1) | AU2015253330A1 (ru) |
BR (1) | BR112016024943A2 (ru) |
CA (1) | CA2945978A1 (ru) |
EA (1) | EA201692180A1 (ru) |
HK (1) | HK1231413A1 (ru) |
IL (1) | IL248470A0 (ru) |
MX (1) | MX2016013944A (ru) |
SG (1) | SG11201608674UA (ru) |
TW (1) | TW201613583A (ru) |
UY (1) | UY36099A (ru) |
WO (1) | WO2015168103A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201606204TA (en) * | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
KR20220035924A (ko) * | 2019-07-22 | 2022-03-22 | 액테리온 파마슈티칼 리미티드 | 다발성 경화증을 치료하는 방법 |
LT3864053T (lt) * | 2019-09-11 | 2023-09-11 | Novartis Ag | Rms gydymas, pakeičiant terapiją |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
US6395750B1 (en) | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US20090048181A1 (en) | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
WO2006076681A2 (en) | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
UA92761C2 (ru) | 2005-10-19 | 2010-12-10 | Тева Фармасьютикл Индастриз, Лтд. | Кристаллы лаквинимода натрия и способ их изготовления |
AU2007258366B2 (en) | 2006-06-12 | 2012-10-25 | Active Biotech, Ab | Stable laquinimod preparations |
JP2009543823A (ja) | 2006-07-17 | 2009-12-10 | ノバルティス アクチエンゲゼルシャフト | 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体 |
DE13169139T1 (de) | 2007-02-08 | 2022-07-14 | Biogen MA Inc. | Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose |
EP2567699A1 (en) | 2007-07-11 | 2013-03-13 | MediciNova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
US8354428B2 (en) | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
EA021227B1 (ru) | 2008-09-03 | 2015-05-29 | Тева Фармасьютикал Индастриз Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
DK2467372T3 (en) | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
SG183515A1 (en) | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
PE20130613A1 (es) | 2010-03-03 | 2013-06-23 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
PT2542079E (pt) | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
US20120010239A1 (en) | 2010-07-09 | 2012-01-12 | Ulf Tomas Fristedt | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
NZ611628A (en) * | 2010-12-07 | 2015-06-26 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
PE20142319A1 (es) | 2011-07-28 | 2015-01-24 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero |
SG10201606204TA (en) * | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
UY34896A (es) * | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod) |
EP2961406A4 (en) | 2012-10-12 | 2017-01-04 | Teva Pharmaceutical Industries Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
AU2014216199A1 (en) | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CA2917587A1 (en) | 2013-07-31 | 2015-02-05 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and flupirtine |
JP2016533323A (ja) | 2013-09-27 | 2016-10-27 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症の治療のためのラキニモド併用療法 |
AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
EP3193870A4 (en) | 2014-09-16 | 2018-04-25 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
-
2015
- 2015-04-28 AU AU2015253330A patent/AU2015253330A1/en not_active Abandoned
- 2015-04-28 KR KR1020167033515A patent/KR20170005434A/ko unknown
- 2015-04-28 UY UY0001036099A patent/UY36099A/es not_active Application Discontinuation
- 2015-04-28 US US14/698,319 patent/US20150306088A1/en not_active Abandoned
- 2015-04-28 EA EA201692180A patent/EA201692180A1/ru unknown
- 2015-04-28 JP JP2016565045A patent/JP2017514824A/ja active Pending
- 2015-04-28 EP EP15785579.2A patent/EP3137092A4/en not_active Withdrawn
- 2015-04-28 CA CA2945978A patent/CA2945978A1/en not_active Abandoned
- 2015-04-28 SG SG11201608674UA patent/SG11201608674UA/en unknown
- 2015-04-28 WO PCT/US2015/027961 patent/WO2015168103A1/en active Application Filing
- 2015-04-28 CN CN201580023414.9A patent/CN106573014A/zh active Pending
- 2015-04-28 MX MX2016013944A patent/MX2016013944A/es unknown
- 2015-04-28 BR BR112016024943A patent/BR112016024943A2/pt not_active Application Discontinuation
- 2015-04-29 TW TW104113774A patent/TW201613583A/zh unknown
- 2015-11-19 US US14/946,586 patent/US9662322B2/en not_active Expired - Fee Related
-
2016
- 2016-10-25 IL IL248470A patent/IL248470A0/en unknown
-
2017
- 2017-02-13 US US15/431,236 patent/US20170151224A1/en not_active Abandoned
- 2017-05-24 HK HK17105252.3A patent/HK1231413A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201608674UA (en) | 2016-11-29 |
EP3137092A4 (en) | 2017-10-11 |
US9662322B2 (en) | 2017-05-30 |
US20160074378A1 (en) | 2016-03-17 |
JP2017514824A (ja) | 2017-06-08 |
TW201613583A (en) | 2016-04-16 |
EP3137092A1 (en) | 2017-03-08 |
CN106573014A (zh) | 2017-04-19 |
AU2015253330A1 (en) | 2016-12-01 |
KR20170005434A (ko) | 2017-01-13 |
US20150306088A1 (en) | 2015-10-29 |
CA2945978A1 (en) | 2015-11-05 |
HK1231413A1 (zh) | 2017-12-22 |
MX2016013944A (es) | 2017-01-09 |
BR112016024943A2 (pt) | 2018-06-26 |
IL248470A0 (en) | 2016-12-29 |
UY36099A (es) | 2016-02-29 |
WO2015168103A1 (en) | 2015-11-05 |
US20170151224A1 (en) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
EA201692180A1 (ru) | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации | |
MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
MD20160007A2 (ru) | Ингибиторы RORC2 и способы их применения | |
EA201792575A1 (ru) | Фармацевтические композиции леветирацетама пролонгированного высвобождения | |
CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
MA40535A (fr) | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 | |
NZ727456A (en) | Fused triterpene compounds and uses thereof | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
CL2015003563A1 (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos. | |
EA201791525A2 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
BR112015024877A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose |